Associate Director
Pfizer
Mohamed Hassanein has a combined academic and industry experience of nearly 15 years in translational research, biomarkers and regulated bioanalysis across multiple therapeutic areas including oncology, IO, rare and infectious diseases.
Mohamed received his master’s degree in Biological Sciences from Delaware State University, PhD in Molecular Biology and Genetics from University of Delaware and post-doctoral training at Vanderbilt Ingram Cancer Center where he later became a Research Assistant Professor. At Vanderbilt his research focused on the discovery and validation of novel therapeutic targets and biomarkers for early detection and treatment of lung cancer.
Mohamed is the present Vice-Chair of AAPS Biomarker and Precision Medicine Community. He is currently a precision medicine and clinical biomarker lead at Pfizer providing end-to-end biomarker strategy support for multiple rare diseases and gene therapy programs.
Disclosure information not submitted.
Monday, October 17, 2022
9:30 AM – 10:30 AM ET
Wednesday, October 19, 2022
1:30 PM – 2:30 PM ET